CVS Health Nasdaq'tan Daha mı İyi Performans Gösteriyor?

Is CVS Health Outperforming the Nasdaq?

Kritika Sarmah

Fri, September 4, 2026 at 2:55 PM GMT+3 3 min read

• CVS -0.47%
• ^IXIC -0.29%

CVS Health Corporation (CVS), based in Woonsocket, Rhode Island, is a leading health solutions company providing accessible, affordable, and personalized healthcare, with a market capitalization of $80.1 billion. The company serves more than 100 million people through local and national channels, using pharmacies, technology, and connected services to improve health outcomes and make care more convenient.

Companies worth $10 billion to $200 billion are generally described as "large-cap stocks," and CVS Health definitely fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and position within the healthcare plans industry. Its market leadership stems from its extensive network of convenient locations, with most U.S. consumers living close to a CVS store. Its partnership with Teladoc and focus on digital health services further strengthen its ability to provide convenient, technology-driven healthcare and attract modern consumers.

More News from Barchart

Despite its notable strengths, CVS has slipped 12.2% from its 52-week high of $110.68, reached on July 22, 2026. Over the past three months, CVS stock has climbed 6.4%, significantly outperforming the Nasdaq Composite ($NASX), which declined 1% during the same period.

Shares of CVS have gained 22.5% year-to-date and 32.6% over the past 52 weeks, outperforming the Nasdaq Composite's 14.4% year-to-date gain and 23.7% return over the past year.

While CVS has been trading above its 200-day moving average since early April, it dipped below its 50-day moving average since early August.

CVS has benefited from improving operating performance, with lower medical costs at Aetna, a favorable drug mix, and consecutive earnings beats supporting investor sentiment. The company's decision to raise its 2026 earnings outlook further reinforces expectations for continued improvement.

On August 5, CVS shares fell about 5.1% after the company reported its Q2 results. Despite the decline, adjusted EPS of $2.58 surpassed Wall Street expectations of $1.87, while total revenue of $106.1 billion exceeded forecasts of $100.16 billion.

More recently, CVS Health made its updated 2026–27 flu vaccines available nationwide at CVS Pharmacy and MinuteClinic, positioning the company to benefit from seasonal vaccination demand. With 63% of surveyed consumers likely to get a flu shot and expanded testing and treatment services, the move could support pharmacy traffic and healthcare revenues.

Within the competitive healthcare plans industry, top rival UnitedHealth Group Incorporated (UNH) has slightly underperformed CVS, advancing 21.5% year-to-date and 30.2% over the past 52 weeks.

Wall Street analysts are bullish on CVS's prospects. The stock has a consensus "Strong Buy" rating from the 24 analysts covering it. The mean price target of $114.25 suggests a 17.5% premium to its current price.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com